Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 27;12(12):1109. doi: 10.1038/s41419-021-04100-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A A total of 106 pairs of fresh CRC tumors and matched adjacent tissues were assessed by flow cytometry analysis, and the representative images are shown. B The expression levels of HER2 in fresh tissues of CRC patients (n = 106, ^***P < 0.001, two-tailed t-test). C The expression levels of HER2 in fresh tissues of CRC patients with different progression. (*P < 0.05, ***P < 0.001, Kruskal–Wallis test followed by the Dunn’s multiple comparison test). D The difference in the expression levels of HER2 between fresh CRC tumors and matched adjacent tissues (Cancer% - Adjacent%) of CRC patients with different progression (^***P < 0.001, two-tailed t-test). E Left panel: The levels of HER2 in TMA were evaluated by IHC analysis, and the representative staining images are shown. The scale bar is marked in each image. Right panel: The difference in staining score between CRC lesions and adjacent tissues (Cancer - Adjacent) in Xuzhou, Nanjing, and combined cohorts are shown. F KM curves depicting the overall survival of CRC patients based upon tumoral HER2 levels. Left to right: Xuzhou, Nanjing, and combined cohorts. G KM curves depicting the overall survival of mCRC patients based upon tumoral HER2 levels. P values were calculated by the Log-rank test. H Multivariable COX regression analyses (adjusted age, gender, location, grade, TNM stage and HER2 expression) were performed in our cohorts. Bars correspond to 95% confidence interval (CI). HR hazard ratio.